Overview

This trial is active, not recruiting.

Condition jaw, edentulous, partially
Treatment straumann® bone level slactive implant (4.1mm diameter)
Sponsor Institut Straumann AG
Start date June 2008
End date November 2011
Trial size 24 participants
Trial identifier NCT00906165, CR 05/07

Summary

The study is designed to evaluate the clinical and radiographic outcomes of Straumann® Bone Level Implant SLActive placed in healed alveolar ridge (at least 8 weeks post extraction) and immediately provisionalised versus the same type of implants placed in healed alveolar ridge but not provisionalised. In both cases the implants will be loaded at 16 weeks (final restorations). The outcomes will be evaluated over a 2-year period.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking single blind (investigator)
Primary purpose treatment
Arm
(Active Comparator)
The Straumann® Bone Level SLActive Implant (4.1mm diameter) will be immediately provisionalized upon placement, i.e. impressions will be taken directly after implant installation in order to fabricate screw-retained resin crowns within 48 hours after implant placement. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
straumann® bone level slactive implant (4.1mm diameter)
Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)
(Active Comparator)
The Straumann® Bone Level SLActive Implant (4.1mm diameter) will not be immediately provisionalized, instead there will be delayed implant loading. i.e. the patient will receive a removable prosthesis if necessary and the impressions for the final restoration will be taken 12-14 weeks after implant installation. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
straumann® bone level slactive implant (4.1mm diameter)
Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)

Primary Outcomes

Measure
radiographic bone level change at the mesial and distal of the implants between baseline and one year post treatment
time frame: between baseline and one year post treatment

Secondary Outcomes

Measure
Success and Survival rate of the implants
time frame: 1 year and 2 years after implant placement and at 1,3,5 years for patients who consented to extended follow up (up to 5 years post implant placement)
Complication rate (adverse events and/or implant failure) of the implants and implant overstructure
time frame: 1 year and 2 years after implant placement and at 3,4,5 years after implant placement for patients who consent to participate in the extension period
Probing Pocket Depth
time frame: Recorded at 16 weeks, 6 months, 12 months, 24 months after implant placement and at 36 months, 48 months, 60 months post implant placement for patients consenting to participate in the extension period
Gingival Recessions (REC)
time frame: Recorded at 16 weeks, 6 months, 12 months, 24 months after implant placement and at 36 months, 48 months and 60 months post implant placement for patients consenting to participation in the extension period
Soft tissue changes
time frame: Recorded at 16 weeks, 6 months, 12 months, 24 months after implant placement and at 36 months, 48 months, 60 months post implant placement for patients consenting to participation in the extension period
Adverse Events
time frame: From randomization to 5 years after implant placement

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - General inclusion criteria - Males and females, age 18 to 75 years of age (the subjects should be legally able to give informed consent to the procedure; age limitation is also present to avoid inclusion of subjects with incomplete cranio-facial growth). - Absence of relevant medical conditions. Patients with contributing medical history in which any elective oral surgical intervention would be contraindicated should be excluded. In particular patients with uncontrolled or poorly controlled diabetes, or unstable or life threatening conditions should be excluded. - Absence of uncontrolled or untreated periodontal disease. - Absence of untreated caries lesions. - Patient in good medical and psychological health as documented by self assessment - Patient's availability for follow-up according to the protocol. - Local inclusion criteria - A single tooth replacement is required in the incisor, canine, pre-molar and first molar region. Multiple-implant restorations (non adjacent to the test implant) can be performed during the study (not to be included as test implants). - at least 8 weeks post extraction where the soft tissues of the socket have healed - Presence of at least one adjacent tooth - Presence of adequate native bone to achieve primary stability Exclusion Criteria: - General exclusion criteria - Patients who have any known diseases (not including controlled diabetes mellitus), infections or recent surgical procedures within 30 days of study initiation. - Female patients who are pregnant or lactating or of child bearing potential not using acceptable methods of birth control (hormonal, barriers or abstinence). - Patients who are on chronic treatment (i.e., two weeks or more) with any medication known to affect oral status (e.g., phenytoin, dihydropyridine, calcium antagonists, cyclosporine) within one month of baseline visit. - Patients who are on concomitant anticoagulant therapy of warfarin (coumadine), clopidogrel, ticlopidine or once daily aspirin of more than 81 mg. - Patients who knowingly have HIV or Hepatitis. - Physical handicaps that would interfere with the ability to perform adequate oral hygiene. - Patients who have undergone administration of any investigational drug within 30 days of study initiation. - Alcoholism or chronically drug abuse causing systemic compromisation. - Patients who are heavy smokers (>10/cigarettes per day). - Patients suffering from a known psychological disorder. - Patients who have limited mental capacity or language skills such that study information cannot be understood, informed consent cannot be obtained or simple instructions cannot be followed. - Exclude patients with BOP > 30% at the completion of the pre-treatment phase. - Local exclusion criteria - Exclude experimental sites with inadequate bone availability where initial stability of the implant cannot be achieved or extended augmentation procedures and/ or sinus nasal lift are required. - History of local radiation therapy. - Presence of severe oral lesions. - Severe bruxism or clenching habits - Patients with lack of posterior occlusion and severely reduced vertical dimension of occlusion - Patients presenting clinical and radiological signs and symptoms of maxillary sinus disease in the implant area. - Patients presenting an acute endodontic lesion in the neighboring areas to the experimental procedure (sites with presence of an asymptomatic chronic lesion are eligible) - Plaque score > 30%

Additional Information

Official title The Role of Immediate Provisional Restorations on Bone Level Implants. A Randomised, Single Blind Controlled Clinical Trial
Principal investigator Nikos Donos, Prof. Dr.
Description This is a prospective, randomised, controlled, single blind, and single center study. The total study duration for each patient should be 24 months. Straumann Bone Level Ø 4.1 mm SLActive implants will be placed for single tooth replacement, followed by either immediate provisional prosthetic loading or no provisionalised. The final prosthetic loading is made at 16 weeks after implant loading. The implant length will be selected according to the clinical indication of the site based on previous radiographic evaluation. In total 11 visits per patient are scheduled in this study. Bone level changes, implant success and survival rate, soft tissue changes, aesthetic outcome and adverse events (AEs) will be assessed. The study devices are CE- (Conformité Européenne, meaning European Conformity) marked products. One center in the United Kingdom will participate.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Institut Straumann AG.